Psychoeducation and compliance in the treatment of Schizophrenia: Results of the Munich psychosis information project study

Journal of Clinical Psychiatry

Volumn 67, Issue 3, 2006, Pages 443-452

  Pitschel Walz, Gabriele ^a   Bäuml, Josef ^a   Bender, Wolfram ^b   Engel, Rolf R ^c   Wagner, Michael ^d   Kissling, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Psychiatric Hospital Haar   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; PERAZINE; RISPERIDONE; ZOTEPINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; FAMILY RELATION; FEMALE; FOLLOW UP; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH ORGANIZATION; MENTAL HEALTH RESEARCH; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SURVIVAL RATE;

EID: 33645763729     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0316     Document Type: Article

References (47)

1. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(suppl 16):14-17
2. Kissling W, Leucht S. Results of treatment of schizophrenia: is the glass half full or half empty? Int Clin Psychopharmacol 1999;14(suppl 3): S11-S14
3. Jeffreys SE, Harvey CA, McNaught AS, et al. The Hampstead Schizophrenia Survey 1991, 1: prevalence and service use comparisons in an inner London health authority, 1986-1991. Br J Psychiatry 1997;170:301-306
4. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997;68:377-392
5. Kissling W. Ideal and reality of neuroleptic relapse prevention. Br J Psychiatry Suppl 1992;18:133-139
6. Gaebel W, Pietzcker A. One-year outcome of schizophrenic patients: the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 1985;18:235-239
7. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66
8. Rettenbacher MA, Hofer A, Eder U, et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry 2004;65:1211-1218
9. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
10. Nosé M, Barbui C, Gray R, et al. Clinical interventions for treatment non-adherence in psychosis: meta-analysis. Br J Psychiatry 2003;183: 197-206
11. Bäuml J, Pitschel-Walz G, eds. Psychoedukation bei Schizophrenen Erkrankungen. Stuttgart, Germany: Schattauer; 2003
12. Wiedemann G, Klingberg S, Pitschel-Walz G, et al. Psychoeducational interventions in the treatment of patients with schizophrenic disorders. Nervenarzt 2003;74:789-808
13. CONSORT Group. CONSORT Flowchart. Available at: http://www.consort- statement.org/Downloads/flowchart.pdf. Accessibility verified Feb 20, 2006
14. Bäuml J, Pitschel-Walz G, Kissling W. Psychoedukative gruppen bei schizophrenen psychosen für patienten und angehörige. In: Stark A, ed. Verhaltenstherapeutische Ansätze im Umgang mit Schizophren Erkrankten. Tübingen, Germany: dgvt-Verlag; 1996:217-255
15. Bäuml J. Psychosen aus dem Schizophrenen Formenkreis. Ein Ratgeber für Patienten und Angehörige. Berlin, Germany: Springer; 1994
16. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
17. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771
18. Bäuml J, Pitschel-Walz G, Basan A, et al. Die auswirkungen des Protektiven potentials von angehörigen auf den langzeitverlauf schizophrener psychosen: ergebnisse der 7-Jahreskatamnese der Münchner PIP-Studie. In: Binder W, Bender W, eds. Die Dritte Dimension in der Psychiatrie-Angehörige, Betroffene und Professionelle auf Einem Gemeinsamen Weg. Cologne, Germany: Claus Richter Verlag; 2003:129-159
19. Bäuml J, Pitschel-Walz G, Bindl W, et al. Belastungen von angehörigen: vergleich von patienten mit und ohne psychoedukation [abstract]. Nervenarzt 2003;74(suppl 2):S50
20. Pitschel-Walz G, Boemer R, Mayer C, et al. Psychoeducational groups for schizophrenic patients and their relatives: influence on knowledge, attitudes and familial expressed emotions [abstract]. Pharmacopsychiatry 1993:26
21. Pitschel-Walz G, Boemer R, Mayer C, et al. Effects of psychoeducational groups for schizophrenic patients and their relatives on knowledge, compliance and relapse [abstract]. Pharmacopsychiatry 1995:28
22. Pitschel-Walz G. Die Einbeziehung der Angehörigen in die Behandlung Schizophrener Patienten und ihr Einfluß auf den Krankheitsverlauf. Frankfurt am Main, Germany: Peter Lang; 1997
23. Jahn T, Mussgay L. Die statistische kontrolle möglicher medikamenteneinflüsse in experimentalpsychologischen schizophreniestudien: ein Vorschlag zur berechnung von chlorpromazinäquivalenten. Z Klin Psychol 1989;18:257-267
24. Mojtabai R, Nicholson RA, Carpenter BN. Role of psychosocial treatments in management of schizophrenia: a meta-analytic review of controlled outcome studies. Schizophr Bull 1998;24:569-587
25. Pekkala E, Merinder L. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2002:CD002831
26. Pitschel-Walz G, Leucht S, Bäuml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia: a meta-analysis. Schizophr Bull 2001;27:73-92
27. Tarrier N, Barrowclough C, Porceddu K, et al. The Salford Family Intervention Project: relapse rates of schizophrenia at five and eight years. Br J Psychiatry 1994;165:829-832
28. Hornung WP, Feldmann R, Klingberg S, et al. Long-term effects of a psychoeducational psychotherapeutic intervention for schizophrenic outpatients and their key-persons: results of a five-year follow-up. Eur Arch Psychiatry Clin Neurosci 1999;249:162-167
29. Macpherson R, Jerrom B, Hughes A. A controlled study of education about drug treatment in schizophrenia. Br J Psychiatry 1996;168:709-717
30. Zygmunt A, Olfson M, Boyer CA, et al. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002;159: 1653-1664
31. Linden M, Nather J, Wilms HU. Zur definition, bedeutung und messung der krankheitskonzepte von patienten: die krankheitskonzeptskala (KK-Skala) für schizophrene patienten. Fortschr Neurol Psychiatr 1988;56:35-43
32. Hornung WP, Schonauer K, Feldmann R, et al. Medication-related attitudes of chronic schizophrenic patients: a follow-up study after psycho-educational intervention. Psychiatr Prax 1998;25:25-28
33. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-108
34. Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003;54:719-723
35. Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000;61:382-386
36. Cabeza IG, Amador MS, Lopez CA, et al. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000;41:349-355
37. Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004;65:354-360
38. Freudenreich O, Cather C, Evins AE, et al. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004;65:1372-1376
39. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-222
40. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
41. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic non-compliance. Schizophr Res 2004;66:51-57
42. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128
43. Lam YF, Velligan DI, DiCocco M, et al. Comparative assessment of antipsychotic adherence by concentration monitoring, pill count and self-report [poster]. Presented at the 9th biennial International Congress on Schizophrenia Research; March 29-April 2, 2003; Colorado Springs, Colo
44. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005;133:129-133
45. Basan A, Pitschel-Walz G, Bäuml J. Psychoedukative Gruppen bei schizophrenen patienten und anschließende ambulante langzeitbehandlung. Fortschr Neurol Psychiatr 2000;68:537-545
46. Rummel-Kluge C, Pitschel-Walz G, Bäuml J, et al. Psychoeducation in schizophrenia: results of a survey of all psychiatric institutions in Germany, Austria, and Switzerland. Schizophr Bull. In press
47. Bäuml J, Behrendt B, Bender M, et al. Arbeitsgruppe Psychoedukation. Konsensuspapier zu psychoedukativen interventionen bei schizophrenen erkrankungen. In: Bäuml J, Pitschel-Walz G, eds. Psychoedukation bei Schizophrenen Erkrankungen. Stuttgart, Germany: Schattauer; 2003: 1-35